GE Healthcare

Peter Ehrenheim

GE Healthcare expands its life sciences business

President & CEO

"Our current business focus and strengths are in the areas of bioprocessing, proteins, cellular analysis, cell handling and tools for cell therapy. Our strategic intent is to add adjacent technologies or applications which can add value to the overall customer solutions we provide. We are particularly excited about the sample collection and storage opportunity with the FTA product line.We have a strong footprint in Asia and Japan and with access to this, the team at Whatman will be able to grow its global business."

1. What is the reason behind choosing Whatman Plc. among other filtration product companies?

GE Healthcare's Life Sciences business provides technologies for cellular and protein science research and tools used in the manufacture of biopharmaceuticals such as vaccines, cell therapies and antibodies. Whatman supplies filtration products and technologies and has a well-recognised brand and a strong sector expertise. It also has a broad product offering of filters and membranes for the laboratory, life sciences research and medical technology industries.

Whatman's product offering is very much complementary to our Life Sciences portfolio. So their expertise in filtration and their products are a great addition to our business, especially in the area of sample preparation and membrane components for diagnostic kits.

2. What synergies does GE Healthcare expect from Whatman's acquisition?

This deal is well aligned with our strategic intent to add adjacent technologies and/or applications which can add value to the overall customer solutions we provide.

On completion of the deal, we would look for synergies that make sense for the business with a focus on additional revenue opportunities. There are a number of areas where we think GE Healthcare has the ability to accelerate initiatives already underway at Whatman.

3. Do you think there is a delay in entering in to this segment of business despite GE Healthcare's wide product portfolio and global presence? If so what are the reasons?

There has been no delay on our part in entry to the filtration segment. GE Healthcare continually evaluates the market and the industry in search of appropriate opportunities to sustain our growth. As such, we try to ensure that we enter the right markets at the right times and in the right way, whether that be through acquisition, or through organic growth.

4. How do you think GE Healthcare can leverage the strengths of Whatman in consolidating its position in the filtration product segment?

The Life Sciences business is a key area of growth for GE Healthcare, and Whatman's expertise in filtration technologies and sample preparation adds to our established reputation in protein purification and analysis. This acquisition provides us additional innovative technologies and expertise in life sciences, and is part of our growth strategy as a provider of enabling technologies in protein and gene science. We are particularly excited about the sample collection and storage opportunity with the FTA product line. We have a strong footprint in Asia and Japan and with access to this, the team at Whatman will be able to grow its global business.

5. What are the plans of GE Healthcare in bringing out new products and entering new markets post-acquisition of Whatman?

Our current business focus and strengths are in the areas of bioprocessing, proteins, cellular analysis, cell handling and tools for cell therapy. We are looking to continue our organic growth in these areas as well as grow by acquisition. Our strategic intent is to add adjacent technologies or applications which can add value to the overall customer solutions we provide.

TOP